Overview

Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.

Status:
Terminated
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
Inhaled Iloprost will be administered to near term infants with Persistent Pulmonary Hypertension of the Newborn in two different doses in order to test safety and efficacy in reducing pulmonary artery pressure.
Phase:
Phase 4
Details
Lead Sponsor:
University of Chicago
Treatments:
Iloprost